1. Introduction {#s0005}
===============

Alzheimer\'s disease (AD), the most common neurodegenerative disorder, is increasingly prevalent among those aged 65 years and over. AD prevalence is projected to triple by the year 2050 ([@bb0005]) making it vital to achieve early and accurate diagnosis and to discover disease-modifying therapies. The only feasible approach for presymptomatic diagnosis to date is through the use of biomarkers.

Hippocampal atrophy is the most established AD structural imaging biomarker. Hippocampal atrophy is seen in normal aging, yet in the latent AD stages hippocampal atrophy becomes greatly accelerated ([@bb0025; @bb0030; @bb0035; @bb0020; @bb0015; @bb0010]). Hippocampal atrophy shows strong correlation with cognitive decline ([@bb0040; @bb0045; @bb0050]) and with AD pathologic markers such as neuronal and neurofibrillary tangle counts and Braak and Braak pathological stages ([@bb0075; @bb0060; @bb0055; @bb0065; @bb0070]).

Cerebrospinal fluid (CSF) measures of amyloid beta protein (Aβ) and tau are the most established AD fluid biomarkers. Pathologic Aβ deposition in the brain tissue is thought to occur early in the disease course and is associated with low CSF Aβ~42~ levels ([@bb0080]). CSF total tau (t-tau) and phosphorylated tau (p-tau) are significantly elevated in subjects with AD ([@bb0085; @bb0090; @bb0095; @bb0100]) and are thought to reflect neurodegeneration of tau-containing neurons. Unlike CSF Aβ~42~ ([@bb0105]), CSF t-tau and p-tau changes occur later in the disease course and are associated with cognitive decline ([@bb0115; @bb0110; @bb0120; @bb0105]).

Several research groups have independently investigated the individual accuracy of these biomarkers to differentiate cognitively normal elderly, MCI and AD subjects ([@bb0085; @bb0135; @bb0125; @bb0130; @bb0100; @bb0145; @bb0140; @bb0150]). Yet while biomarker changes are clearly present years before AD is diagnosed, no single biomarker can adequately predict conversion to AD or serve as a diagnostic tool with an acceptable level of accuracy.

Many groups including ours have made important strides towards multimodal biomarker diagnostic discrimination ([@bb0155; @bb0170; @bb0165; @bb0175; @bb0160; @bb0185; @bb0180]). Here we combined imaging and CSF biomarker data from the Alzheimer\'s Disease Neuroimaging Initiative-1 (ADNI-1) dataset to compare the performance of unimodal (hippocampal atrophy or CSF biomarkers alone) and multimodal (hippocampal atrophy, CSF variables and ApoE genotype combined) biomarker classifiers for differentiating NC, MCI and AD. We also examined to what extent the amyloid (i.e., CSF Aβ~42~) and the neurodegenerative biomarkers (CSF tau, CSF p-tau and hippocampal atrophy) play a role for differentiating different disease stages from each other and for predestining conversion to AD. In addition we sought to determine the effect of ApoE4 genotype on diagnostic accuracy and biomarker selection.

2. Materials and methods {#s0010}
========================

2.1. Subjects {#s0030}
-------------

Data used preparing this article were obtained from the ADNI database ([www.loni.ucla.edu/ADNI](http://www.loni.ucla.edu/ADNI){#ir0090}). ADNI is the result of efforts of many co-investigators from a broad range of academic institutions and private corporations; subjects have been recruited from over 50 sites across the U.S. and Canada. For up-to-date information, please see [www.adni-info.org](http://www.adni-info.org){#ir0095}.

ADNI-1 enrolled approximately 400 amnestic MCI, 200 mild AD and 200 NC subjects, aged 55--90. Written informed consent was obtained from all participants. The clinical description of the ADNI-1 cohort was recently published ([@bb0190]). The full list of inclusion/exclusion criteria may be accessed online at <http://www.adni-info.org/Scientists/ADNIGrant.aspx>.

As all ADNI subjects had serial 1.5T MRI images, their inclusion in our analyses was largely determined by the availability of CSF data. CSF measures were performed in only a subset of the ADNI subjects. 111 NC, 182 MCI and 95 AD ADNI participants had both structural MRI and CSF assessment at baseline. 191 subjects (49%; 27 NC, 99 MCI, 65 AD) were apolipoprotein E4 (ApoE4) carriers and 197 (51%; 84 NC, 83 MCI, 30 AD) were noncarriers. Additionally 21 NC, 14 MCI and 3 AD subjects were ApoE2 carriers.

As one of the main goals of ADNI is to carefully track biomarker changes in NC and MCI predestined to convert to AD, we also analyzed which combination of biomarkers can predict conversion to AD. We used all available MCI subjects who had either converted to AD at any point between baseline and month 36 (MCI converters, N = 80) or remained stable all the way to month 36 (MCI nonconverters, N = 80). 22 MCI subjects dropped out before month 36 without converting to AD and were excluded from our analyses.

2.2. CSF biomarker data {#s0015}
-----------------------

We downloaded the baseline CSF Aβ~42~, t-tau and the tau phosphorylated at threonine at position 181 (p-tau~181~) data from the ADNI website (<http://www.loni.ucla.edu/ADNI>) in October 2008. CSF collection and transportation protocols, and procedural details on CSF Aβ~42~, t-tau and the p-tau~181~ measurements are provided in the ADNI procedural manual posted at <http://www.adni-info.org> and in a recent publication by Shaw et al. ([@bb0150]).

2.3. MRI preprocessing {#s0035}
----------------------

All subjects were scanned with a standardized high-resolution MRI protocol (<http://www.loni.ucla.edu/ADNI/Research/Cores/index.shtml>) on scanners developed by one of three manufacturers (General Electric Healthcare, Siemens Medical Solutions and Philips Medical Systems) with a protocol optimized for best contrast to noise in a feasible acquisition time ([@bb0200; @bb0195]). Raw data with an acquisition matrix of 192 × 192 × 166 and voxel size 1.25 × 1.25 × 1.2 mm^3^ in the x-, y-, and z-dimensions was subjected to in-plane, zero-filled reconstruction (i.e., sinc interpolation) resulting in a 256 × 256 matrix and voxel size of 0.9375 × 0.9375 × 1.2 mm^3^. Image quality was inspected at the ADNI MRI quality control center at the Mayo Clinic (in Rochester, MN, USA) ([@bb0200]). Phantom-based geometric corrections, image non-uniformity and bias field corrections were applied ([@bb0205; @bb0200; @bb0210; @bb0215]). Both the uncorrected and corrected image files are freely available to interested researchers at <http://www.loni.ucla.edu/ADNI>.

2.4. Hippocampal segmentation {#s0040}
-----------------------------

The preprocessed baseline 1.5 T 3D T1-weighted scans were downloaded and linearly registered to the International Consortium for Brain Mapping (ICBM-53) brain template ([@bb0220]) using the Minctracc algorithm and 9-parameter (9P) transformation (3 translations, 3 rotations, 3 scales) ([@bb0225]). The aligned images were resampled in an isotropic space of 220 voxels along each axis (*x*, *y*, and *z*) resulting in a final voxel size of 1 mm^3^. The hippocampi were segmented with our recently developed and validated automated machine-learning hippocampal segmentation technique (AdaBoost) which uses the adaptive boosting approach originally proposed by [@bb0230] as previously described ([@bb0255; @bb0240; @bb0245; @bb0250; @bb0235]). Hippocampal volumes were extracted.

2.5. Statistical methods {#s0045}
------------------------

### 2.5.1. Demographic comparisons {#s0050}

We used one-way Analyses of Variance (ANOVA) with post hoc Bonferroni correction for multiple comparisons to examine diagnostic differences in age, education, MMSE, CSF biomarker levels and hippocampal volume at baseline, and chi-squared test to determine differences in sex distribution between each diagnostic group. For comparison of baseline demographic and biomarker measures between ApoE4-positive and negative subjects and MCI converters (MCIc) and MCI nonconverters (MCInc) we used a two-tailed Student\'s t-test for continuous variables, and a chi-squared test for categorical variables.

### 2.5.2. Support vector machines classifier {#s0055}

SVMs are popular machine learning algorithms, formulated to learn patterns in training data and classify new testing data. The mathematical principle by which SVM performs pattern recognition is by finding a multidimensional plane that maximizes the margin between data points in different classes ([@bb0265]). SVMs have been particularly successful in biological classification problems, as non-linear kernels can be introduced to the algorithm so that non-planar, multidimensional surfaces can instead be used to classify patterns of data. In our study, we implemented the radial basis function (RBF) kernel and optimized its width or *γ* parameter (as well as the SVM cost or *C* parameter) through grid search using the e1071 package ([@bb0270]) in R (<http://cran.r-project.org>). Often, addition of non-contributory features can reduce classification performance. For this reason, we ranked our features based on the elements of a linear SVM\'s normal vector (i.e., \|*w~i~*\|; ([@bb0275])) and iteratively removed those with lower weights to find sets of features that yield maximal classification accuracies.

We trained the SVM algorithm with CSF, ApoE4 and imaging measures for subjects with known diagnoses and used the leave-one-out approach to predict each new subject\'s diagnostic category. This process was repeated *n* times and the machine\'s predictive accuracy was measured by summing up the correct and incorrect classifications. All classifiers included age, sex, and educational level (in years). Next, we obtained receiver operating characteristic (ROC) curves for the predictions to additionally assess the classifier\'s sensitivity, specificity and area under the curve (AUC) characteristics.

Our classifier results were further subjected to multiple comparisons correction by permutation analyses. We ran 10,000 permutations of the dependent variable (clinical diagnosis) against the sets of individual biomarker characteristics for each individual classifier and defined a final single corrected *p*-value for each ROC.

3. Results {#s0060}
==========

3.1. Demographic characteristics {#s0065}
--------------------------------

The demographic characteristics of the diagnostic groups are shown in [Tables 1--3](#t0005 t0010 t0015){ref-type="table"}. There were no significant age or educational differences between the diagnostic groups. The MCI group had significantly more males relative to both the NC and the AD groups (p = 0.023). As expected, AD subjects had the lowest mean MMSE and CSF Aβ~42~ and NC the highest (p \< 0.001). The opposite was seen for CSF t-tau and p-tau (both p \< 0.001). The MCI group was intermediate on these variables ([Table 1](#t0005){ref-type="table"}).

ApoE4-positive NC subjects had significantly lower CSF Aβ~42~ (p \< 0.001) and higher CSF p-tau levels (p = 0.024) relative to ApoE4-negative NC. ApoE4-positive MCI subjects also showed significantly lower CSF Aβ~42~ (p \< 0.001), higher CSF tau and p-tau (both p \< 0.001) relative to ApoE4-negative MCI subjects. ApoE4-positive AD subjects were significantly less educated (p = 0.02) and had lower CSF Aβ~42~ levels (p = 0.001) relative to ApoE4-negative AD subjects ([Table 2](#t0010){ref-type="table"}).

Relative to MCI nonconverters, MCI converters had significantly lower MMSE (p = 0.014), higher proportion of ApoE4 carriers (p = 0.004), lower hippocampal volume (p = 0.022) and CSF Aβ~42~ (p = 0.001), and higher CSF tau (p = 0.002) and p-tau (p = 0.001, [Table 3](#t0015){ref-type="table"}).

3.2. Classifier results {#s0070}
-----------------------

### 3.2.1. Cross-sectional classifiers {#s0020}

[Fig. 1](#f0005){ref-type="fig"} and [Table 4](#t0020){ref-type="table"} show the cross-sectional classifier ROCs, classifier performance metrics, ranking of variables selected by each classifier and permutation corrected classifier significance.

#### 3.2.1.1. NC vs. MCI classifiers ([Fig. 1](#f0005){ref-type="fig"} top portion first row) {#s0075}

The hippocampal NC vs. MCI classifier achieved an AUC of 0.68. The features selected by the classifier included hippocampal volume, age and sex. The permutation corrected classifier significance was p~corrected~ \< 0.0001.

The CSF NC vs. MCI classifier achieved an AUC of 0.77. The features selected by the classifier included CSF Aβ~42~, CSF tau, sex and age. The permutation corrected classifier significance was p~corrected~ \< 0.0001.

ApoE4 genotype performed as well as hippocampal volume and CSF biomarkers regardless of whether ApoE2 carriers were excluded or not (all subjects AUC = 0.7, p~corrected~ \< 0.0001, without ApoE2 carriers AUC = 0.71, p~corrected~ \< 0.0001). Substituting the binary ApoE4-positive vs. negative predictor variable with a variable reflecting the number of ApoE4 alleles (0, 1 or 2) did not result in overall improvement in classifier performance (AUC = 0.67, p~corrected~ \< 0.0001).

The multimodal NC vs. MCI classifier presented with all three CSF variables, hippocampal volume, age, sex and education achieved an AUC of 0.78. The variables selected by the classifier included CSF Aβ~42~, CSF tau, hippocampal volume, sex, and age. The permutation corrected classifier significance was p~corrected~ \< 0.0001. The addition of ApoE4 genotype did not seem to affect the overall multimodal classifier results (AUC = 0.79, p~corrected~ \< 0.0001, [Table 6](#t0030){ref-type="table"}).

Direct statistical comparison showed that the CSF NC vs. MCI classifier performed significantly better than the hippocampal NC vs. MCI classifier (p = 0.01). The hippocampal + CSF classifier performed better than the hippocampal-only (p = 0.0044) but not the CSF-only (p = 0.65) classifiers. Adding ApoE4 genotype to the multimodal hippocampal + CSF classifier did not result in a statistically significant difference (p = 0.56).

#### 3.2.1.2. NC vs. AD classifier ([Fig. 1](#f0005){ref-type="fig"} top portion second row) {#s0080}

The hippocampal NC vs. AD classifier achieved an AUC of 0.78. The features selected by the classifier included hippocampal volume, age, and education. The permutation corrected classifier significance was p~corrected~ \< 0.0001.

The CSF NC vs. AD classifier achieved an AUC of 0.85. The features selected by the classifier included CSF Aβ~42~, CSF tau and p-tau, sex, education and age. The permutation corrected classifier significance was p~corrected~ \< 0.0001.

ApoE4 genotype performed about the same as the hippocampal volume and worse than CSF regardless of whether ApoE2 carriers were excluded or not (all subjects AUC = 0.76, p~corrected~ \< 0.0001, without ApoE2 carriers AUC = 0.74, p~corrected~ \< 0.0001). Substituting the binary ApoE4-positive vs. negative predictor variable with a variable reflecting the number of ApoE4 alleles (0, 1 or 2) did not result in overall improvement in classifier performance (AUC = 0.78, p~corrected~ \< 0.0001).

The multimodal NC vs. AD classifier presented with all CSF variables, hippocampal volume, age, sex and education achieved an AUC of 0.90. The variables selected by the classifier included CSF tau, CSF Aβ~42~, hippocampal volume, age, CSF p-tau and sex. The permutation corrected classifier significance was p~corrected~ \< 0.0001. The addition of ApoE4 genotype did not affect the overall multimodal classifier results (AUC = 0.88, permutation corrected significance p~corrected~ \< 0.0001, [Table 6](#t0030){ref-type="table"}).

Direct statistical comparison showed that CSF NC vs. AD classifier performed significantly better than the hippocampal NC vs. AD classifier (p = 0.04), and the hippocampal + CSF classifier performed better than the hippocampal-only (p = 0.0001) and the CSF-only (p = 0.03) classifiers. Adding ApoE4 genotype to the multimodal hippocampal + CSF classifier did not result in a statistically significant difference (p = 0.43).

#### 3.2.1.3. MCI vs. AD classifier ([Fig. 1](#f0005){ref-type="fig"} top portion bottom row) {#s0085}

The hippocampal MCI vs. AD classifier achieved an AUC of 0.53. The features selected by the classifier included education and hippocampal volume. The permutation corrected classifier significance was p~corrected~ = 0.024.

The CSF MCI vs. AD classifier achieved an AUC of 0.61. The single feature selected by the classifier was CSF p-tau. The permutation corrected classifier significance was p~corrected~ \< 0.001.

ApoE4 genotype performed about the same as the hippocampal volume and worse than CSF regardless of whether ApoE2 carriers were excluded or not (all subjects AUC = 0.52, p~corrected~ \< 0.0001, without ApoE2 carriers AUC = 0.51, p~corrected~ \< 0.0001). Substituting the binary ApoE4-positive vs. negative predictor variable with a variable reflecting the number of ApoE4 alleles (0, 1 or 2) did not result in overall improvement in classifier performance (AUC = 0.53, p~corrected~ \< 0.0001).

The multimodal MCI vs. AD classifier presented with all CSF variables, hippocamapal volume age, sex and education achieved an AUC of 0.62. The variables selected by the classifier included hippocampal volume, CSF p-tau, sex and CSF tau. The permutation corrected classifier significance was p~corrected~ \< 0.001. The addition of ApoE4 genotype did not seem to affect the overall multimodal classifier results (AUC = 0.61, permutation corrected significance p~corrected~ = 0.0011, [Table 6](#t0030){ref-type="table"}).

Direct statistical comparison showed no statistically significant improvement in performance between the various classifiers.

#### 3.2.1.4. ApoE4 stratified analyses ([Fig. 1](#f0005){ref-type="fig"} bottom portion) {#s0090}

Hippocampal volume and CSF biomarkers both separately and in combination performed well in discriminating NC vs. AD regardless of ApoE4 genotype (ApoE4-positive subjects: hippocampal classifier AUC = 0.74 p~corrected~ \< 0.0001, CSF classifier AUC = 0.73 p~corrected~ = 0.0005 and combined classifier AUC = 0.83 p~corrected~ \< 0.0001; ApoE4-negative subjects: hippocampal classifier AUC = 0.73 p~corrected~ = 0.0002, CSF classifier AUC = 0.88 p~corrected~ \< 0.0001 and combined classifier AUC = 0.87 p~corrected~ \< 0.0001).

In the NC vs. MCI analyses CSF biomarkers alone and the combination of hippocampus and CSF biomarkers achieved reasonable AUCs in the ApoE4-negative sample only (ApoE4-negative subjects: hippocampal lassifier AUC = 0.70 p~corrected~ = 0.008, CSF classifier AUC = 0.78 p~corrected~ = 0.0008 and combined classifier AUC = 0.79 p~corrected~ = 0.003; ApoE4-positive subjects: hippocampal classifier AUC = 0.64 p~corrected~ = 0.005, CSF classifier AUC = 0.52 p~corrected~ = 0.01 and combined classifier AUC = 0.58 p~corrected~ = 0.0006).

In the MCI vs. AD analyses the hippocampal classifier performed best in ApoE4-positive subjects (AUC = 0.69, p~corrected~ = 0.0006) and the CSF classifier performed best in the ApoE4-negative subjects (AUC = 0.74, p~corrected~ \< 0.0001).

Among ApoE4-positive subjects classifiers did not prove to be statistically significant from each other. Among ApoE4-negative subjects the hippocampal + CSF classifier was significantly better than the hippocampal-only classifier when discriminating NC vs. MCI (p = 0.012) and NC vs. AD (p = 0.008, [Table 6](#t0030){ref-type="table"}). The CSF-only classifier performed significantly better than the hippocampal-only classifier when discriminating Apoe4-negative NC vs. AD subjects (p = 0.012, [Table 6](#t0030){ref-type="table"}).

### 3.2.2. Predicting conversion {#s0025}

[Fig. 2](#f0010){ref-type="fig"} and [Table 5](#t0025){ref-type="table"} show the SVM classifier ROCs, classifier performance metrics, ranking of variables selected by each classifier and permutation corrected classifier significance for the MCI conversion classifier analyses.

In the classifier model including both ApoE4-positive and negative subjects the hippocampal-only classifier selected hippocampal volume, sex and education and achieved an AUC = 0.64 (p~corrected~ = 0.048). The CSF-only classifier selected only CSF Aβ~42~ and achieved an AUC = 0.63 (p~corrected~ = 0.008). The combined hippocampal-CSF classifier selected hippocampal volume, CSF Aβ~42~, CSF p-tau, education, sex and CSF tau and achieved an AUC = 0.64 (p~corrected~ = 0.042). The addition of ApoE4 genotype did not seem to affect the overall multimodal classifier results (AUC = 0.68, p~corrected~ = 0.019). ApoE4 genotype performed about the same as hippocampal volume and CSF regardless of whether ApoE2 carriers were excluded or not (all subjects AUC = 0.64, p~corrected~ = 0.002, without ApoE2 carriers AUC = 0.61, p~corrected~ = 0.004). Substituting the binary ApoE4-positive vs. negative predictor variable with a variable reflecting the number of ApoE4 alleles (0, 1 or 2) did not result in overall improvement in classifier performance (AUC = 0.61, p~corrected~ = 0.0026).

Once stratified by ApoE4 genotype the best results for predicting conversion to AD were achieved by the hippocampus-only classifier in ApoE4-positive (predictors: hippocampal volume and sex; AUC = 0.68, p~corrected~ \< 0.0001) and CSF-only classifier for ApoE4-negative subjects (predictors: CSF p-tau, education and sex; AUC = 0.89, p~corrected~ \< 0.0001).

4. Discussion {#s0095}
=============

All classifier models performed very well in discriminating NC from AD and moderately well in discriminating NC from MCI. The MCI vs. AD ascertainment, as expected, proved to be more challenging for unimodal and multimodal classifiers alike presumably due to the fact that the MCI biomarker pattern is rather similar to the one seen in AD. The multimodal biomarker classifier approach had better diagnostic and predictive power than any unimodal classifier.

Several important observations can be made from the discriminative classifier performance. CSF Aβ~42~ played a significant role in discriminating NC from MCI and AD but was not selected by the MCI vs. AD classifiers while CSF p-tau contributed to accurate discrimination of AD from both NC and MCI, yet played no role in differentiating NC from MCI. These observations are in agreement with the proposed biomarker trajectory in AD where amyloid markers become abnormal early in the disease course and neurodegenerative markers (here CSF p-tau) become abnormal later in the disease course. Interestingly hippocampal atrophy and CSF t-tau seemed quite ubiquitously used by most classifiers including the NC vs. MCI classifiers, suggesting that these neurodegenerative biomarkers are becoming abnormal somewhere between the CSF Aβ~42~ and the CSF p-tau changes.

CSF Aβ~42~ proved to be useful for differentiating NC from MCI only among ApoE4-negative but not ApoE4-positive subjects. This is likely due to the fact that many ApoE4-positive cognitively normal elderly already have significant brain amyloidosis and low CSF Aβ~42~ rendering amyloid biomarkers insensitive for differentiating NC and MCI. At the same time neurodegenerative biomarkers (CSF tau, CSF p-tau and/or hippocampal atrophy) were readily chosen in both ApoE4-positive and ApoE4-negative NC vs. MCI classifiers establishing their discriminative role for patients with either genotype.

Both amyloid and neurodegenerative biomarkers were readily chosen by the conversion classifiers. Similar to the observations of others ([@bb0155; @bb0170; @bb0165; @bb0160; @bb0180]) the classifier accuracies in the full sample were marginal at best. However once split by ApoE4 genotype we observed that hippocampal volume and sex were helpful for predicting conversion to AD among ApoE4-positive MCI, while CSF p-tau was helpful for the prediction of conversion to AD among ApoE4-negative MCI subjects. Both classifier algorithms chose only markers of neurodegeneration as one might expect to be the case in the symptomatic MCI stage. These conclusions are well supported by data from a recent paper by Jack et al. showing that among amyloid positive MCI subjects hippocampal atrophy, and not amyloid burden, predicted shorter time to progression to dementia ([@bb0280]) because amyloid load plateaus ([@bb0285]) while hippocampal volume does not ([@bb0280]).

The CSF outperformed the hippocampal metrics in discriminating NC from MCI and AD. Low CSF Aβ~42~ is tightly linked to the presence of amyloid pathology in the brain while hippocampal atrophy is criticized for being a nonspecific measure observed in many disease states and in normal aging ([@bb0290]). Techniques capable of detecting hippocampal atrophy in selected subfields are being developed ([@bb0035; @bb0295; @bb0300; @bb0305]) and some have even demonstrated ability to detect hippocampal atrophy in the presymptomatic disease stages ([@bb0295]). Alternatively more sophisticated MRI measures such as for instance the Structural Abnormality Index (STAND), which captures hippocampal and cortical atrophy, can also improve the ability of MRI for predicting future decline ([@bb0310; @bb0315]).

In contrast to other groups that have published multimodal diagnostic classification papers using ADNI data ([@bb0155; @bb0170; @bb0165; @bb0175; @bb0160; @bb0185; @bb0180]) we also investigated classifier performance after ApoE4-stratification (i.e., investigated the classifier performance separately in carriers and noncarriers). This led to some interesting observations in respect to the modulatory effect of ApoE4 genotype on biomarker trajectory in AD. It is fascinating that support vector machine classifiers can help uncover interesting observations in respect to AD pathophysiology. This is a novel way of utilization of a statistical methodology thought by many to be only capable of diagnostic discrimination and outcome prediction.

Although multicollinearity can be a problem for multiple linear regression, it is standard for SVMs to be provided with thousands of correlated predictors, and still perform very well. Only certain kinds of machine learning methods, such as naive Bayes methods, assume that the inputs of the classifier are statistically independent. Even when inputs considered to be an n-dimensional vector by SVM, are highly correlated, the SVM will find the optimal hyperplane for separating the samples and making decisions to categorize or classify future data.

Correlation among inputs is less of an issue when making predictions. Redundancy among predictors is common and does not undermine the predictive accuracy of the classifier. However correlated inputs do tend to complicate the interpretation of which predictor variables are driving the effects. This is more of an issue if the classifier is considered as a "descriptive" model --- telling us the relative importance of variables for the prediction, but it is less of an issue for predictive accuracy as many of the redundant predictors can be used.

When one fits an SVM with multiple predictors, if the predictors are correlated, SVM might pick some predictors on one occasion and may do equally well on another occasion using other predictors. SVM will always pick the one that minimizes the error. Sometimes the accuracies of certain feature combinations are very close, yet SVM will pick the one with the lowest error. It does not mean that the other dropped variables might not be predictive, only that they are sufficiently redundant with the ones that were used that they were not chosen.

This study has several strengths and limitations. The strengths of ADNI lie in its large size, its detailed cognitive assessment protocol and careful diagnostic ascertainment, as well as in the implementation of unified MRI and CSF collection and processing strategies across multiple sites and the meticulous data quality control. Yet ADNI was designed to inform decisions about future disease modifying clinical trials and as such it employs the rigorous inclusion and exclusion criteria typical of clinical trials. As such, the ADNI cohort is not a complete representation of the elderly population and its findings should be generalized with caution; for example, the classification accuracies may be poorer in populations with a great mix of conditions and co-morbidities. Another relative weakness of our study is the etiologic/pathologic uncertainty in the MCI stage as at least 30% of amnestic MCI subjects have been found to harbor non-AD pathology ([@bb0320]). Even so, etiologic heterogeneity should not be expected to invalidate the biomarker-to-biomarker correlations across the pooled sample.

Another important limitation of our study is the classifiers\' exclusive reliance on biomarkers for diagnostic categorization. By doing so we inadvertently compromise our ability to accurately classify AD vs. MCI subjects as the diagnostic distinction between these categories is determined by the presence or absence of functional decline which cannot be ascertained from biomarker data. Thus it is not surprising that our biomarker-based classifier models failed to discriminate between MCI and AD. However we must acknowledge that providing our classifiers with functional or cognitive variables would have introduced a circularity argument, as cognitive variables were used for diagnostic ascertainment of ADNI subjects.

One must also take under consideration that CSF tau and p-tau changes do not accurately reflect (i.e., lag behind) the severity and extent of tau pathology in the AD brain. CSF biomarkers are just peripheral surrogates of actual tau pathology. Several tau-imaging ligands are currently under development. Such technology might provide a much more accurate metric of tau pathology and contribute meaningfully to an improved understanding and staging of the early and presymptomatic stages of AD. Last but not least, our classifier results will benefit from independent validation in a different cohort with similar longitudinal follow-up and biomarker data availability.
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###### 

Mean demographic and biomarker data.

  Variable at baseline             NC N = 111   MCI N = 182   AD N = 95    One-way ANOVA/chi squared test, p-value
  -------------------------------- ------------ ------------- ------------ -----------------------------------------
  Age, years                       75.5 (5.2)   74.2 (7.4)    74.6 (7.9)   0.3
  Gender, M:F                      56:55        121:61        55:40        **0.023**
  Education, years                 15.8 (2.8)   15.8 (3.0)    15.3 (3.0)   0.3
  MMSE                             29.1 (1.0)   26.9 (1.8)    23.6 (1.9)   **\< 0.001**
  CSF Aβ~42~ level, pg/ml          206 (55)     163 (55)      143 (40)     **\< 0.001**
  CSF t-tau level, pg/ml           69 (30)      103 (61)      124 (58)     **\< 0.001**
  CSF p-tau~181~ level, pg/ml      25 (15)      35 (18)       43 (20)      **\< 0.001**
  Mean hippocampal volume, mm^3^   4100 (586)   3779 (631)    3518 (604)   **\< 0.001**
                                                                           
  ApoE4 positive subjects                                                  
                                                                           
  Variable at baseline             NC N = 27    MCI N = 99    AD N = 65    One-way ANOVA/chi squared test, p-value
                                                                           
  Age, years                       75.8 (5.8)   73.5 (6.6)    74.0 (7.4)   0.3
  Gender, M:F                      18:9         60:39         39:26        0.8
  Education, years                 15.6 (2.8)   15.7 (2.8)    14.8 (3.0)   0.2
  MMSE                             28.9 (1.1)   27.0 (1.8)    23.6 (1.9)   **\< 0.001**
  CSF Aβ~42~ level, pg/ml          157(49)      143 (41)      131 (27)     **0.012**
  CSF t-tau level, pg/ml           80 (40)      117 (67)      122 (53)     **0.007**
  CSF p-tau~181~ level, pg/ml      32 (21)      40 (18)       43 (19)      **0.05**
  Mean hippocampal volume, mm^3^   4175 (443)   3708 (608)    3476 (608)   **\< 0.001**
                                                                           
  ApoE4 negative subjects                                                  
                                                                           
  Variable at baseline             NC N = 84    MCI N = 83    AD N = 30    One-way ANOVA/chi squared test, p-value
                                                                           
  Age, years                       75.4 (5.0)   74.9 (8.2)    75.9 (8.9)   0.8
  Gender, M:F                      38:46        61:22         14:16        **0.001**
  Education, years                 15.8 (2.7)   16.0 (3.2)    16.3 (2.8)   0.7
  MMSE                             29.1 (1.0)   26.8 (1.8)    23.5 (1.9)   **\< 0.001**
  CSF Aβ~42~ level, pg/ml          222 (48)     187 (60)      168 (52)     **\< 0.001**
  CSF t-tau level, pg/ml           65 (25)      85 (48)       127 (69)     **\< 0.001**
  CSF p-tau~181~ level, pg/ml      22 (11)      30 (16)       42 (22)      **\< 0.001**
  Mean hippocampal volume, mm^3^   4077 (625)   3731 (573)    3610 (564)   **\< 0.001**

Bold values indicate significance at p \< 0.05.

###### 

Demographic and biomarker comparisons by ApoE genotype using a two-tailed t-test for continuous and a chi-squared test for categorical variables (p-values are shown; for mean and SD for each variable, please see [Table 1](#t0005){ref-type="table"}).

  Variable at baseline             MCI ApoE4 + vs ApoE4 -   MCI ApoE4 + vs. ApoE4 -   AD ApoE4 + vs ApoE4 -
  -------------------------------- ------------------------ ------------------------- -----------------------
  Age, years                       0.7                      0.2                       0.3
  Gender, M:F                      0.053                    0.07                      0.5
  Education, years                 0.8                      0.5                       **0.02**
  MMSE                             0.4                      0.6                       0.8
  CSF Aβ~42~ level, pg/ml          **\< 0.001**             **\< 0.001**              **0.001**
  CSF t-tau level, pg/ml           0.07                     **\< 0.001**              0.8
  CSF p-tau~181~ level, pg/ml      **0.024**                **\< 0.001**              0.9
  Mean hippocampal volume, mm^3^   0.5                      0.8                       0.3

Bold values indicate significance at p \< 0.05.

###### 

Baseline demographic and biomarker comparisons of MCI converters vs. nonconverters using a two-tailed t-test for continuous and a chi-squared test for categorical variables.

  Variable at baseline             MCI converters   MCI nonconverters   Two-tailed t-test/chi squared test, p-value
  -------------------------------- ---------------- ------------------- ---------------------------------------------
  Age, years                       74.8 (7.1)       73.6 (7.5)          0.3
  Gender, M:F                      48:32            55:25               0.3
  Education, years                 15.5 (3.0)       16.3 (2.8)          0.1
  ApoE4 positive:negative          53:27            35:45               **0.004**
  MMSE                             26.6 (1.8)       27.3 (1.7)          **0.014**
  CSF Aβ~42~ level, pg/ml          145 (40)         172 (60)            **0.001**
  CSF t-tau level, pg/ml           113 (51)         88 (47)             **0.002**
  CSF p-tau~181~ level, pg/ml      40 (16)          31 (17)             **0.001**
  Mean hippocampal volume, mm^3^   3600 (569)       3803 (542)          **0.022**

Bold values indicate significance at p \< 0.05.

###### 

Classifier performance metrics, ranking of variables selected by each classifier, and permutation corrected classifier significance.

![](t1)

###### 

Classifier performance metrics, ranking of variables selected by each classifier and permutation corrected classifier significance in predicting conversion from MCI to AD with and without stratification by ApoE4 genotype.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                  Hippocampal classifier   CSF classifier   Hippocampal + CSF classifier   Hippocampal + CSF + ApoE classifier                                                               
  --------------- ------------------------ ---------------- ------------------------------ ------------------------------------- --------------------- --------------- --------------------- ---------------
  MCIc vs MCInc   Hippocampal\             Accuracy 64%\    CSF Aβ~42~                     Accuracy 68%\                         Hippocampal volume\   Accuracy 67%\   ApoE CSF p-tau\       Accuracy 68%\
                  volume\                  AUC 0.64\                                       AUC 0.63\                             CSF Aβ~42~\           AUC 0.64\       Hippocampal volume\   AUC 0.68\
                  Sex\                     p = 0.048                                       p = 0.008                             CSF p-tau\            p = 0.042       CSF Aβ~42~\           p = 0.019
                  Education                                                                                                      Education\                            CSF tau\              
                                                                                                                                 Sex\                                  Education             
                                                                                                                                 CSF tau                                                     

                                                                                                                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -------------------------------------------------------------------------------------------------------------------------------------
  ApoE4 stratified MCIc vs. MCInc classifier                                                                              
  -------------------------------------------- -------------- --------------- ------------ --------------- -------------- -------------
  ApoE4 + MCIc vs. ApoE4 + MCInc               Hippocampal\   Accuracy 76%\   Age\         Accuracy 69%\   Hippocampal\   Accuracy\
                                               volume\        AUC 0.68\       Sex          AUC 0.63\       volume\        76%\
                                               Sex            p \< 0.0001                  p = 0.002       Sex            AUC 0.68\
                                                                                                                          p \< 0.0001

  ApoE4 − MCIc vs. ApoE4 − MCInc               Sex\           Accuracy 72%\   CSF p-tau\   Accuracy 78%\   CSF p-tau      Accuracy\
                                               Age            AUC 0.70\       Education\   AUC 0.89\                      75%\
                                                              p = 0.005       Sex          p \< 0.0001                    AUC 0.77\
                                                                                                                          p \< 0.001
  -------------------------------------------------------------------------------------------------------------------------------------

###### 

Statistical comparisons of classifiers (p-values).

  Diagnostic comparison                                       Classifier Comparison            p-value
  ----------------------------------------------------------- -------------------------------- ---------
  NC vs. MCI                                                  Hippocampal vs. CSF classifier   0.01
  Hippocampus + CSF vs. hippocampal classifier                0.0044                           
  Hippocampus + CSF vs. CSF classifier                        NS                               
  Hippocampus + CSF + ApoE vs. hippocampus + CSF classifier   NS                               
  NC vs. AD                                                   Hippocampal vs. CSF classifier   0.04
  Hippocampus + CSF vs. hippocampal classifier                0.0001                           
  Hippocampus + CSF vs. CSF classifier                        0.03                             
  Hippocampus + CSF + ApoE vs. hippocampus + CSF              NS                               
  MCI vs. AD                                                  Hippocampal vs. CSF classifier   NS
  Hippocampus + CSF vs. hippocampal classifier                NS                               
  Hippocampus + CSF vs. CSF classifier                        NS                               
  Hippocampus + CSF + ApoE vs. hippocampus + CSF classifier   NS                               
  ApoE4 + NC vs. MCI                                          Hippocampal vs. CSF classifier   NS
  Hippocampus + CSF vs. hippocampal classifier                NS                               
  Hippocampus + CSF vs. CSF classifier                        NS                               
  Hippocampus + CSF + ApoE vs. hippocampus + CSF classifier   NS                               
  ApoE4 + NC vs. AD                                           Hippocampal vs. CSF classifier   NS
  Hippocampus + CSF vs. hippocampal classifier                NS                               
  Hippocampus + CSF vs. CSF classifier                        NS                               
  Hippocampus + CSF + ApoE vs. hippocampus + CSF classifier   NS                               
  ApoE4 + MCI vs. AD                                          Hippocampal vs. CSF classifier   NS
  Hippocampus + CSF vs. hippocampal classifier                NS                               
  Hippocampus + CSF vs. CSF classifier                        NS                               
  Hippocampus + CSF + ApoE vs. hippocampus + CSF classifier   NS                               
  ApoE4 − NC vs. MCI                                          Hippocampal vs. CSF classifier   NS
  Hippocampus + CSF vs. hippocampal classifier                0.012                            
  Hippocampus + CSF vs. CSF classifier                        NS                               
  Hippocampus + CSF + ApoE vs. hippocampus + CSF classifier   NS                               
  ApoE4 − NC vs. AD                                           Hippocampal vs. CSF classifier   0.012
  Hippocampus + CSF vs. hippocampal classifier                0.008                            
  Hippocampus + CSF vs. CSF classifier                        NS                               
  Hippocampus + CSF + ApoE vs. hippocampus + CSF classifier   NS                               
  ApoE4 − MCI vs. AD                                          Hippocampal vs. CSF classifier   NS
  Hippocampus + CSF vs. hippocampal classifier                NS                               
  Hippocampus + CSF vs. CSF classifier                        NS                               
  Hippocampus + CSF + ApoE vs. hippocampus + CSF classifier   NS                               

NS---not significant.

[^1]: Data used in preparing this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([www.loni.ucla.edu/ADNI](http://www.loni.ucla.edu/ADNI){#ir0080}). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but only some participated in analysis or writing of this report. A complete listing of ADNI investigators is available at <http://adni.loni.ucla.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>.
